Back
October 20, 2024

Poor insights on what stimulates long-lived antibody production could spur false hope for better Covid-19 vaccines….

I had sworn to withdraw from social media due to all the superficiality, but some of my followers keep
asking for my opinion regarding the interpretation of certain new publications, such as the one mentioned
under https://www.science.org/content/article/missing-immune-cells-may-explain-why-covid-19-vaccine-protection-quickly-wanes


Once again, I am disgusted by the simplistic interpretation of several immunological phenomena by
dogma-traumatized scientists. For example, this article suggests that the absence of long-lived plasma
cells (LLPCs) specific to SARS-CoV-2 (SC-2) is due to the fact that the distance between two neighboring
spike (S) proteins on the viral membrane is too large to allow crosslinking by receptors on B cells. As if S
proteins were grafted onto a rigid membrane at a specific distance from each other!! Have these scientists
never heard that cell membranes, and therefore also virus membranes of enveloped viruses, are fluid and
that the proteins anchored in them can move to come closer together or move further apart?

It is now known and repeatedly documented that mRNA vaccines do not lead to the maturation of fully
functional and long-lived IgG1 antibodies (Abs) after the second injection. As described in my book
(https://bit.ly/3NYokkE), mRNA vaccines lead to immune refocusing, where suboptimal Abs are induced
against immune subdominant or immune-recessive epitopes on the S protein. That this unnatural and
weak, aberrant stimulation of the adaptive immune system does not induce LLPCs specific to SC-2 is
therefore logical.

The fact that LLPCs specific to SC-2 are also barely detectable in unvaccinated individuals who have had
one or more SC-2 infections, however, has a completely different reason. The innate immune system of
healthy, unvaccinated individuals is usually able to control the virus to a large extent, so that only weak
stimulation of the adaptive immune system is required to finally eliminate the virus. This was certainly the
case at the beginning of the pandemic when the circulating lineages were still relatively low in
infectiousness. However, as the immune escape pandemic continued to evolve and the innate immune
system of the unvaccinated became better and better trained, the contribution of their adaptive immune
system to controlling the virus remained relatively minor. Consequently, immunological memory of B cells
was barely triggered; in any case, not sufficiently to generate significant amounts of LLPCs specific to SC-
2. But why did these investigators fail to test the generation of SC-2-specific LLPCs in unvaccinated subjects
who contracted severe disease? Such individuals obviously experienced strong stimulation of their
adaptive immune system and likely generated plenty of LLPCs specific to SC-2.

Last, even though Covid-19 (C-19) vaccines based on virus-like particles (VLPs) may improve the
immunogenicity of the S protein, the catastrophic failure of the C-19 mass vaccination program is not due
to the poor quality or longevity of anti-S Abs, but rather to the fact that large-scale immunization.
campaigns during the pandemic drove viral immune escape, turning the natural pandemic into an artificial
immune escape pandemic

Support our work
DONATE
Subscribe to our Substack Newsletter

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.

Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.

Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.

Email: info@voiceforscienceandsolidarity.org

Recent Posts
December 19, 2024

Dynamics of SARS-CoV-2 in highly C-19 vaccinated populations in a nutshell

Read
December 2, 2024

Are Newly Emerging Saltation Variants the Desperate Harbingers of an Imminent Surge in COVID-19 Case Fatalities in Highly C-19 Vaccinated Populations?

Read
November 23, 2024

Bird Flu Gain-of-Function Study Fueling Vaccine Development, Fears of Human Transmission

Read
Voices for Science and solidarity, © 2023